Your session is about to expire
← Back to Search
CC-486 for Follicular Lymphoma
Study Summary
This trial is testing a 3-drug combination to treat minimally pretreated follicular lymphoma that has progressed despite other therapies. The goal is to find a safe and tolerable dose, and to compare the effectiveness of this combination to the current standard of care.
- Follicular Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you please enumerate the experiments involving CC-486 that have already taken place?
"Currently, there are 400 studies involving CC-486 with 61 of them in the advanced testing phase. Most of these trials originate out of Edmonton, Alberta; however 12605 other sites across the world are also participating in clinical research surrounding this drug."
What is the ceiling for participants in this clinical research?
"Indeed, clinicaltrials.gov reveals that the study is actively recruiting participants - having been posted on September 1st 2021 and recently updated on November 12th 2021. The trial requires 50 patients from a single medical centre to be enrolled."
Are there vacancies in this experiment open to participants?
"Affirmative. Clinicaltrials.gov reveals that this research endeavor, which was released on September 1st 2021, is actively recruiting participants. Fifty volunteers must be recruited from a single medical centre."
What outcomes is this clinical trial attempting to accomplish?
"This trial, which is planned to run for 336 days in total, seeks to identify the Maximum Tolerable Dose of Venetoclax and CC-486 via observation of associated Side Effects according to CTCAE Criteria Version 5. Additionally, Secondary aims include determining how many participants no longer exhibit signs of Follicular lymphoma after receiving three cycles of combined oral therapy (as identified by PET Scan per Lugano Criteria), measuring average time spent living with Follicular Lymphoma without worsening symptoms at study end and five years later, as well as calculating when half the Expansion Group are still alive post treatment using Median"
In what contexts is CC-486 typically administered?
"Induction chemotherapy is commonly managed with CC-486, and this medication may also be beneficial for managing refractory anemias, leukemia, myelocytic disorders, acute cases of multilineage dysplasia."
Share this study with friends
Copy Link
Messenger